In December 2023, Bandaram Pharma reported net sales of Rs 5.70 crore, marking a substantial increase of 411.55% from Rs 1.12 crore in December 2022. The quarterly net profit for December 2023 was Rs 0.05 crore, showing a notable 41.57% decrease from Rs 0.09 crore in December 2022. EBITDA (earnings before interest, tax, depreciation, and amortization) reached Rs 0.07 crore in December 2023, indicating a 22.22% decrease from Rs 0.09 crore in December 2022.
Bandaram Pharma’s earnings per share (EPS) declined to Rs 0.04 in December 2023 from Rs 0.29 in December 2022. On February 26, 2024, Bandaram Pharma shares closed at Rs 31.88 on the BSE, providing a return of 14.51% over the last 6 months and a -56.30% return over the last 12 months.